Date | Company | Amount | Funding type | Investors | Therapeutic area | Type of Information |
---|---|---|---|---|---|---|
2011-11-16 | Arcarios (The Netherlands) | €920K | grant | Flemish agency for Innovation by Science and Technology (IWT) (Belgium) |
Grant | |
2011-11-14 | Azellon Cell Therapeutics (UK) | £0.65 million | IP Group (UK) - Oxford Technology Management (UK) - Hugh Osmond | Regenerative medicine | Fundraising | |
2011-11-11 | Genable Technologies (Ireland) | € 5 million | series B financing round | Fountain Healthcare Partners (ireland) Delta Partners (USA - CA) | Rare diseases - Genetic diseases | Series B financing round |
2011-11-08 | ORCA Therapeutics (The Netherlands) | € 5 million | credit | Agentschap NL (The Netherlands) | Cancer - Oncology | Subvention |
2011-11-07 | Somantix (The Netherlands) VU University Medical Center Amsterdam (The Netherlands) | € 1.5 million | grant | EuroTransBio (European Commission initiative to foster cross border research & development between companies and academia working in the biotech industry) (UE) | Cancer - Oncology | Grant |
2011-11-04 | Genfit (France) | €93,500 | private placement | Yorkville Advisors LLC (USA) | Cardiovascular diseases - Metabolic diseases - Liver diseases | Private placement |
2011-11-03 | Curevac (Germany) | $110 Million (€100 million) | private placement | Baillie Gifford (UK) Chartwave Limited (UK) Coppel family, Elma Investments, Sigma Group, dievini Hopp BioTech holding (Germany) Dietmar Hopp (Germany) the Bill & Melinda Gates Foundation (USA) | Cancer - Oncology | Private placement |
2011-11-02 | Fresenius (Germany) | €100 million | private placement via issuance of senior notes | |||
2011-11-02 | Genfit (France) | €500,000 | private placement | Cardiovascular diseases - Metabolic diseases - Liver diseases | Private placement | |
2011-11-01 | Domainex (UK) | £250,000 (€ 291 156) | grant | Technology Strategy Board (UK) | Cancer - Oncology | Grant |
2011-10-27 | Bind Biosciences (USA - MA) | $47.25 million | series D financing round | Rusnano (Russian Federation) DHK Investment (India) Polaris Venture Partners (USA - MA) ARCH Venture Partners (USA - IL) Endeavour Vision (Switzerland) NanoDimension (USA - CA) private investors | Series D financing round | |
2011-10-26 | OctoPlus (the Netherlands) | €4 million | private placement | Technology - Services | Private placement | |
2011-10-26 | Curetis (Germany) | Expansion of the financing round by € 9.6 million | Infectious diseases | Fundraising | ||
2011-10-25 | Prosensa (The Netherlands) | up to €5 million | credit | AgentschapNL (The Netherlands) | Rare diseases - Neuromuscular diseases | Subvention |
2011-10-19 | Arsanis Biosciences (Austria) | € 1.19 million | grant | Austrian Research Promotion Agency (Austria) | Infectious diseases | Grant |
2011-10-18 | Population Genetics (UK) | $5.7 million (€4.15 million) | Technology - Services | Fundraising | ||
2011-10-17 | Hookipa Biotech (Austria) | €7 million | series A financing round | Infectious diseases | Fundraising | |
2011-10-17 | Hoopika Biotech (Austria) | €7 million | series A financing round | Sofinnova Partners (France) Forbion Capital Partners (The Netherlands) | Cancer - Oncology - Infectious diseases | Series A financing round |
2011-10-12 | Affiris (Austria) | $ 1.5 million (€ 1.08 million) | grant | The Michael J. Fox Foundation - MJFF (USA) | Neurodegenerative diseases | Grant |
2011-10-11 | The EUROCALIN Consortium The Consortium consists of Pieris AG (Germany), as project coordinator; Technische Universität München (Germany); Medical University of Innsbruck (Austria); Radboud University Nijmegen Medical Centre (Netherlands); Covance Laboratories Ltd. (UK); Antitope Ltd. (UK); FUJIFILM Diosynth Biotechnologies Ltd.UK Limited (UK); Coriolis Pharma Research GmbH (Germany); FGK Clinical Research GmbH (Germany); and ConsulTech GmbH (Germany). | €6 million | grant | Grant |